Loading…
Loading…
EQUITY / NASDAQ · XNCM
Kiora Pharmaceuticals Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2.56 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 2.56 USD · Volume 3,441
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -2,213,771 USD | — | — |
| Net income | -2,079,010 USD | — | — |
| Cash and cash equivalents | 7,076,533 USD | — | — |
| Total liabilities | 6,919,401 USD | — | — |
| Total equity | 16,856,689 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 7,076,533 USD | — | — | 10,955,359 USD | 8,696,570 USD | 8,696,570 USD | 5,508,899 USD | — |
| Net incomeIncome statement | -2,079,010 USD | -4,496,994 USD | — | -2,417,984 USD | — | -10,835,154 USD | 26,806 USD | -4,318,633 USD |
| Operating profitIncome statement | -2,213,771 USD | -4,723,966 USD | — | -2,510,195 USD | — | -12,831,073 USD | -794,437 USD | -5,520,987 USD |
| Total assetsBalance sheet | 23,776,090 USD | — | — | 21,227,089 USD | 24,253,300 USD | 24,253,300 USD | 29,863,454 USD | — |
| Total equityBalance sheet | 16,856,689 USD | — | 13,934,561 USD | 13,934,561 USD | 16,126,536 USD | 16,126,536 USD | 22,410,742 USD | — |
| Total liabilitiesBalance sheet | 6,919,401 USD | — | — | 7,292,528 USD | 8,126,764 USD | 8,126,764 USD | 7,452,712 USD | — |
| Capital expendituresCash flow statement | — | 28,474 USD | — | 5,018 USD | — | 110,789 USD | — | 32,626 USD |
| Financing cash flowCash flow statement | — | 4,917,989 USD | — | -842 USD | — | 265,655 USD | — | 265,359 USD |
| Investing cash flowCash flow statement | — | -1,488,155 USD | — | 5,400,982 USD | — | 14,426,645 USD | — | 9,077,523 USD |
| Operating cash flowCash flow statement | — | -5,053,267 USD | — | -3,161,332 USD | — | -9,961,176 USD | — | -7,780,721 USD |
| RevenueIncome statement | — | — | — | — | — | 0 USD | 0 USD | 0 USD |
| Report source | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 05/08/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 03/25/2026 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 11/07/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.